Thalidomide for the treatment of patients with myelodysplastic syndromes
- 1 January 2002
- journal article
- Published by Springer Nature in Leukemia
- Vol. 16 (1), 1-6
- https://doi.org/10.1038/sj.leu.2402330
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 14 references indexed in Scilit:
- Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromesMicroscopy Research and Technique, 2000
- Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?Seminars in Hematology, 2000
- Treatment Approaches for Relapsing and Refractory Multiple MyelomaActa Oncologica, 2000
- Angiogenesis in myelodysplastic syndromesBritish Journal of Cancer, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell culturesClinical and Experimental Immunology, 1995
- Thalidomide and the immune system 3. simultaneous up- and down-regulation of different integrin receptors on human white blood cellsLife Sciences, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro studyLeukemia Research, 1991
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982